Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
42% Complete Response At Six Months Matches Auto-CAR-Ts
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.
You may also be interested in...
Precision Biosciences is exiting the allogeneic CAR-T field after four years in early clinical trials, selling off its former lead asset for just $21m.
CB-010 still has a way to go, but data from 16 patients in the ANTLER trial showed a higher six-month CR rate than when the company reported data for five patients at EHA in 2022.
Gilead’s Kite has taken a lead in multiple myeloma cell therapy while Novartis’s first-to-market Kymriah has slumped in sales, but the Swiss drug maker’s new data may support its effort to win on manufacturing time.